Tango Therapeutics, Inc. TNGX
22.87 USD -0.30 (-1.29%)
Nov 4, 2026, 2:13 PM EST
22.76 Day range 24.75
7.37 52-week range 34.39
- YTD
- +158.13%
- 1 year
- +185.52%
Financial health
Altman Z-Score
47.38 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 2
Valuation
P/E -10.2×
FY 2019 5y median -9.2× FY 2025
P/S 16.5×
FY 2019 5y median 18.3× FY 2025
P/B 3.0×
FY 2019 5y median 2.6× FY 2025
P/FCF -7.4×
FY 2019 5y median -7.4× FY 2025
EV/EBITDA -9.6×
FY 2019 5y median -9.2× FY 2025
EV/Sales 15.2×
FY 2019 5y median 15.2× FY 2025
FCF Yield -13.6%
FY 2019 5y median -13.6% FY 2025
Profitability
Gross Margin 96.3%
FY 2019 5y median 100.0% FY 2025
Operating Margin -178.4%
FY 2019 5y median -312.6% FY 2025
Net Margin -162.9%
FY 2019 5y median -278.5% FY 2025
ROE -29.3%
FY 2019 5y median -40.2% FY 2025
ROIC -29.3%
FY 2019 5y median -29.3% FY 2025
ROA -25.5%
FY 2019 5y median -25.3% FY 2025
Growth (YoY)
Revenue 48.3%
FY 2019 FY 2025
Operating Income 23.6%
FY 2019 FY 2025
EPS (diluted) 26.9%
FY 2019 FY 2025
Free Cash Flow -5.8%
FY 2019 FY 2025
Financial Health
Current Ratio 16.3×
FY 2019 5y median 7.5× FY 2025
Quick Ratio 16.3×
FY 2019 5y median 7.5× FY 2025
Debt / Equity 0.1×
FY 2019 5y median 0.2× FY 2025
Net Debt / EBITDA 0.8×
FY 2019 5y median 0.3× FY 2025
Interest Coverage 0.0×
FY 2019 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31
